25683-71-0
Chemical Structure
Terizidone
- CAS No.: 25683-71-0
- Formula:C14H14N4O4
- Molecular Weight:302.29
IUPAC Name: 4,4'-(((1E,1'E)-1,4-phenylenebis(methanylylidene))bis(azanylylidene))bis(isoxazolidin-3-one)
InChIKey: ODKYYBOHSVLGNU-IAGONARPSA-N
SMILES: O=C1NOCC1/N=C/C2=CC=C(/C=N/C3C(NOC3)=O)C=C2
Biological Activity: Terizidone is an antibacterial agent. Terizidone acts as a prodrug to release D-cycloserine (HY-B0030), which competitively inhibits alanine racemase and D-alanine:D-alanine ligase, interfering with peptidoglycan synthesis and thereby inhibiting cell wall assembly in Mycobacterium tuberculosis. Terizidone does not significantly inhibit human liver microsomal CYP1A2 or CYP2C9 enzyme activity. Terizidone can be used in research related to tuberculosis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Terizidone | 98.05% | Terizidone is an antibacterial agent. Terizidone acts as a prodrug to release D-cycloserine (HY-B0030), which competitively inhibits alanine racemase and D-alanine:D-alanine ligase, interfering with peptidoglycan synthesis and thereby inhibiting cell wall assembly in Mycobacterium tuberculosis. Terizidone does not significantly inhibit human liver microsomal CYP1A2 or CYP2C9 enzyme activity. Terizidone can be used in research related to tuberculosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Terizidone-15N2,d6 | Terizidone-15N2,d6 is the deuterated, 15N-labeled Terizidone (HY-112324). Terizidone is an antibacterial agent. Terizidone acts as a prodrug to release D-cycloserine (HY-B0030), which competitively inhibits alanine racemase and D-alanine:D-alanine ligase, interfering with peptidoglycan synthesis and thereby inhibiting cell wall assembly in Mycobacterium tuberculosis. Terizidone does not significantly inhibit human liver microsomal CYP1A2 or CYP2C9 enzyme activity. Terizidone can be used in research related to tuberculosis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Peloquin CA, et al. The treatment of tuberculosis. Clinical Pharmacology & Therapeutics. 2021 Dec;110(6):1455-66.
- [2]. Liwa A C. Pharmacokinetics and dosing rationale of Para-Aminosalicylic acid in children and the evaluation of the in vitro metabolism of Ethionamide, Terizidone and Para-aminosalicylic acid. Stellenbosch: Stellenbosch University; 2012.
